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1. SIRT trials in Asia
1.1. Background
Hepatocellular carcinoma (HCC) is endemic in the
Asia-Paciﬁc region, affecting 10−20 per 100,000 of the
population. Eighty percent of cases are inoperable at
time of diagnosis and HCC is associated with a poor
survival if left untreated. 1 For patients with metastatic
disease, systemic therapy with sorafenib is the reference
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treatment. 2 However, for patients with inoperable local
disease, both sorafenib and locoregional treatments are
recommended in the absence of a recognised ﬁrst-
line treatment. 2 The current evidence indicates that
for patients with intermediate (BCLC stage B) HCC,
median overall survival is ~14 months with sorafenib 3,4
(level 1 evidence) and ~17 months with the locoregional
treatment, selective internal radiation therapy (SIRT)
(level 2 evidence). 5,6
In the light of the encouraging data with SIRT in
inoperable HCC, a number of prospective clinical trials
are currently being conducted both in the Asia-Paciﬁc as
well as in Europe. The results of these trials will deﬁne
the role of SIRT in the management of HCC.
1.2. SIRSA (AHCC05)
1.2.1. Rationale
Ablative therapy such as SIRT with yttrium-90 (90Y)
microspheres is associated with high tumour response,
often resulting in complete or partial destruction of
the tumour. Nevertheless, new lesions can arise within
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ECOG PS = Eastern Cooperative Oncology Group Performance Status
OS = overall survival; TTP = time to tumour progression
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Fig. 1 – SIRveNIB (AHCC06) study design.
the liver or metastasise beyond the liver, which may
be prevented by systemic molecular-pathway targeted
therapy. It has been hypothesised that an efﬁcacious
locoregional therapy such as SIRT followed by a
proven systemic therapy (such as sorafenib) may confer
improved outcomes (in terms of tumour regression,
better locoregional control in terms of time to tumour
progression and improved survival) in advanced HCC.
This hypothesis was tested by the Asia-Paciﬁc HCC Trials
Group in the SIRSA trial.
1.2.2. Study design
SIR-Spheres (90Y-resin microspheres) plus Sorafenib
(SIRSA) was a phase I/II study conducted at 4 centres
in patients with non-resectable HCC in the Asia-Paciﬁc
region (Protocol AHCC05). 7 Sorafenib (400mg b.i.d.)
treatment was initiated 11−14 days after SIRT when only
residual radiation levels were present (half-life of 90Y is
64.1 hours). The primary endpoint was overall response
rate, measured by RECIST 1.0.
1.2.3. Results
Two-thirds of patients were classiﬁed as advanced
(Barcelona Clinic Liver Cancer [BCLC] stage C: 64.7%),
with 57.9% of these patients presenting with major
vascular invasion and 50.0% with extra-hepatic disease.
Forty-four percent of patients had extensive disease
burden with >50% liver involvement. Tumour response
rate was 33.5% and the disease control rate was 79.5%
(including 100% of patients with BCLC stage B and 68% of
patients with BCLC stage C). Median time-to-disease
progression was 9 months (95%CI 6.2–16.8 months) and
overall survival was 20.6 months and 8.2 months in
patients with BCLC stage B and stage C HCC, respectively.
One patient was downstaged to receive transplantation
and two others to receive radiofrequency ablation.
1.3. SIRveNIB (AHCC06)
1.3.1. Rationale
In early 2010, a second phase III trial was discussed
by Asia-Paciﬁc HCC Trials Group at the 5th General
Meeting of the group held in Singapore. The study,
designated SIRveNIB (Protocol AHCC06) 8 was designed
to answer the following question, “For patients with
inoperable locally advanced HCC with no metastases
including those who have progressed following trans-
arterial chemoembolisation (TACE) or RFA or those with
inoperable recurrence after resection, should treatment
be initiated with sorafenib or SIRT?”
1.3.2. Study design
SIRveNIB is an ongoing open-label, randomised-control-
led phase III study in patients without extrahepatic meta-
stases or complete main portal vein thrombosis (PVT)
(branch PVT or incomplete main PVT are permitted)
(Fig. 1). Eligible patients are randomised (1:1) to either
sorafenib or SIRT with 90Y-resin microspheres and are
stratiﬁed by centre and the presence of PVT. The primary
endpoint is overall survival deﬁned as the time from
the date of randomisation to the date of death due
to any cause. Secondary endpoints include: time to
progression, health-related quality of life (HRQoL), safety
and downstaging to curative therapies. Currently, 105 of
the planned 360 patients have been recruited from
26 centres. The ﬁrst interim analysis is expected by the
end of 2012.
2. SIRT trials in Europe
2.1. SORAMIC
2.1.1. Background
The clinical management of HCC requires a comprehen-
sive, multidisciplinary approach. In early HCC, curative
treatment can be achieved by local ablation, resection
or liver transplantation. In intermediate stages of HCC,
patients receive locoregional treatment with palliative
intent (TACE or SIRT with 90Y-radioembolisation). In
patients with advanced disease, systemic therapy with
sorafenib has the potential to prolong survival of patients
and is standard of care in patients with preserved liver
function.
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Fig. 2 – SORAMIC study design.
2.1.2. Study design
Sorafenib in combination with local micro-therapy
guided by gadolinium-EOB-DTPA enhanced MRI in
patients with inoperable HCC (SORAMIC) (EudraCT no.:
2009-012576-27, NCT01126645) is a European multicentre
independent academic trial, involving 41 centres, which
is sponsored by the University of Magdeburg. 9
SORAMIC is composed of three substudies (Fig. 2), with
the following patient groups and primary objectives:
• Substudy 1
– Patients: All eligible patients with inoperable HCC
– Primary objective: To conﬁrm in a 2-step procedure
that Gd-EOB-DTPA enhanced MRI is non-inferior or
superior compared with contrast-enhanced multi-
slice CT for stratiﬁcation of patients to a palliative or
a local ablation treatment strategy.
– Primary endpoint: Correct stratiﬁcation of patients to
a palliative versus local ablation strategy
– Target numbers: 830 patients
• Substudy 2
– Patients: Patients in whom local ablation is appropri-
ate
– Inclusion criteria: Modiﬁed BCLC A up to 4 lesions,
maximum diameter 5 cm; Child–Pugh A
– Primary objective: To determine if sorafenib in com-
bination with RFA prolongs the time-to-recurrence
compared with RFA plus placebo.
– Primary endpoint: Time to recurrence
– Target numbers: 290 patients
• Substudy 3
– Patients: Patients in whom RFA is not appropriate
(palliative treatment group)
– Inclusion criteria: Modiﬁed BCLC B and C (distant
metastases except lung), not eligible for TACE (large
tumours, diffuse disease), Child–Pugh A and B (up to
7 points), bilirubin <30mmol/L
– Primary objective: To determine if the combination of
SIRT using 90Y-resin microspheres and sorafenib im-
proves the overall survival compared with sorafenib
alone.
– Primary endpoint: Overall survival
– Target numbers: 375 patients
The trial started in December 2010 and so far
90 patients have been enrolled, including 50 patients in
the palliative arm and 14 patients in the ablation arm
(update 19th January 2012).
2.1.3. SORAMIC sub-analyses
The academic nature of the trial means that investigators
from all sites have the opportunity to perform sub-
analyses that are not in conﬂict with the main study
endpoint. To date, 12 sub-analyses have begun to answer
a range of questions including: the relationship between
sorafenib plasma levels and treatment response; the
impact of sorafenib or placebo (with RFA) on liver
cirrhosis as assessed by MRI; and the expression proﬁle
of Dickkopf (Dkk) 2 and 4 modulators of Wnt-related
signalling (as part of the sorafenib substudies).
2.2. SARAH
2.2.1. Rationale
The standard of care in France for advanced (BCLC
stage C) HCC is sorafenib. Although there is good
evidence from two randomised controlled trials that
sorafenib is an effective treatment in intermediate and
advanced stage HCC, the incidence of treatment-related
adverse events is high. 3,4
Recently, two large cohort studies of patients with
(mostly advanced) HCC have provided promising results
with SIRT, suggesting efﬁcacy in this indication. 5,6 We
have hypothesised that SIRT could increase the median
overall survival and lower the incidence of treatment-
related adverse events compared with sorafenib.
2.2.2. Study design
SorAfenib versus Radioembolisation inAdvancedHepato-
cellular carcinoma (SARAH) is a prospective randomised
open-labeled trial comparing SIRT with 90Y resin
microspheres and sorafenib in patients with advanced
HCC and no extrahepatic metastases. 10 Patients with
a conﬁrmed diagnosis of HCC will be eligible for the
trial if they present with advanced (BCLC stage C) HCC,
or have failed two sessions of TACE or have recurrent
disease or are not eligible for any other treatment.
The primary endpoint is overall survival. Secondary
objectives include: safety, HRQoL (EORTC QLQ-30 and
HCC18) and a comparison of the health care costs
between the two therapeutic arms.
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This academic trial is promoted by Assistance
Publique-Hoˆpitaux de Paris. The Primary Investigator is
Valerie Vilgrain, Professor of Radiology, Hoˆpital Beaujon,
Clichy, France. Enrolment started in December 2011 and
a total of 400 patients (200 in each treatment arm) are
expected to be recruited from 18 to 20 French academic
centres.
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